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Background: Recent studies supported associations between four NMDA-receptor-mediated signalling genes
(D-amino acid oxidase, DAO; D-amino acid oxidase activator, DAOA; protein phosphatase 3 catalytic subunit gamma
isoform, PPP3CC; dystrobrevin-binding protein 1, DTNBP1) and schizophrenia susceptibility, even though with
contrasting results.
Methods: In an attempt to replicate these findings for the first time in an Italian population, a panel of 32 tagSNPs
was analysed in a representative case-control sample involving 879 subjects.
Results: An association in the allele frequency was observed for the estimated PPP3CC CAG triplotype in the SNP
window rs4872499 T/C-rs11780915 A/G-rs13271367 G/A (pcorrect = 0.001). Similarly, the clustered genotype
frequencies of the estimated/phased CAG triplotype differed between cases and controls (p = 0.004), with the
carriers having a higher frequency in the control population (p = 0.002, odd ratio OR = 0.59, 95% confident interval
CI: 0.43-0.82).
Following the phenotypic dissection strategy, the analysis of single SNPs evidenced a protective effect in males of
rs11780915 and rs13271367 in PPP3CC gene (pcorrect = 0.02, pcorrect = 0.04 respectively). Moreover the estimated/
phased GT diplotype (rs2070586A/G-rs3741775G/T) carriers of the DAO gene were more highly represented in
female controls (p = 0.017, OR = 0.58, 95% CI: 0.37-0.90), as were the estimated/phased CAG triplotype carriers of the
PPP3CC gene in females (p = 0.01, OR = 0.53, 95% CI: 0.32-0.87). In addition, we performed an interaction analysis,
and a 66% (p = 0.003, OR = 0.34, 95% CI: 0.17-0.70) lower risk of developing schizophrenia for female (CAG + GT)
carriers versus non-CAG or -GT carriers was observed. For DTNBP1, we found a protective effect in males for the
rs6459409 (pcorrect = 0.02) and the estimated/phased CT diplotype (rs6459409-rs9476886) carriers (p = 3x10
-4,
OR = 0.46, 95% CI: 0.30-0.70).
In relation to diagnostic subtypes, the estimated/phased DAO GT diplotype and PPP3CC CAG triplotype female
carriers were found to show relative risk ratio (RRR) values of 0.52 and 0.54 lower risk for a paranoid phenotype
respectively.
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Conclusions: Although the results are preliminary and needed replication in a larger sample, this study suggests
that NMDA receptor-mediated signalling genes (DAO, PPP3CC, DTNBP1) might be involved in schizophrenia
pathogenic mechanisms related to gender.
Keywords: tagSNPs, Schizophrenia, Glutamate neurotransmission, DAO, DAOA, PPP3CC, DTNBP1, Association study,
Phenotypic dissectionBackground
D-amino acid oxidase (DAO), D-amino acid oxidase ac-
tivator (DAOA), protein phosphatase 3 catalytic subunit
gamma isoform (PPP3CC), and dystrobrevin-binding
protein 1 (DTNBP1) share the ability to modulate synap-
tic plasticity and glutamatergic transmission trough N-
methyl-D-aspartate receptors (NMDARs) [1]. Because
reduced synaptic plasticity and NMDAR hypofunction
have been increasingly observed in the neurobiology of
schizophrenia [2-4], the genes encoding DAO, DAOA,
PPP3CC, and DTNBP1 may be regarded as plausible
candidates for schizophrenia susceptibility. Recent meta-
analyses have supported this proposal, demonstrating an
allelic association between the four genes and schizo-
phrenia susceptibility [5-8], even though this evidence
does not apply to all of the investigated single nucleotide
polymorphisms (SNPs). A recent convergent functional
genomics in schizophrenia has identified top genes
among which DTNBP1 [9]. In relation to the Italian
population, no data are available with respect to these
genes, except for a specific haplotype association of
DTNBP1 in a small sample report [10].
However, association studies have so far yielded equivo-
cal results. Evidence that some SNPs of the DAO, DAOA,
PPP3CC, and DTNBP1 alleles contribute to conferring an
increased risk of schizophrenia are counterbalanced by
others indicating that they do not increase risk or even
exert a protective effect (www.schizophreniaforum.org/
res/sczgene). Moreover, the Psychiatric Genomics Consor-
tium (PGC) recently published mega-analyses for schizo-
phrenia including 9,394 cases and 12,462 controls that
were combined in a single analysis, and the top 81 statisti-
cally independent loci from that analysis were then tested
in over 8,000 cases [11]. This mega-analysis identified only
seven significant loci that did not involve these four genes.
A number of variables could have contributed to generate
these inconsistent results. Genetic differences associated
with ethnic background, as well as gender effects, the
inherent phenotypic heterogeneity of schizophrenia, and
the presence of epistatic or epigenetic interactions are
rightly considered among the first-line putative sources of
variation that should require a dedicated control; however,
their influence on the putative associations between
the DAO, DAOA, PPP3CC, and DTNBP1 genes andschizophrenia unfortunately remains largely undetermined
to date.
Motivated by these considerations, we planned a case-
control association study that considered the possible
confounding effects of ethnicity and gender, provided a rea-
sonable phenotypic dissection of the patients and tested for
the interactions. Our study evaluated 32 tagSNPs of the
DAO, DAOA, PPP3CC and DTNBP1 genes.
Methods
Case and control samples
The study involved a total of 879 subjects, which in-
cluded 391 DSM-IV-TR - Diagnostic and Statistical
Manual of Mental Disorders [12] schizophrenia patients
and 488 healthy volunteers. Patients and controls were
enrolled and diagnosed as described in detail elsewhere
[13]. In particular patients and controls, enrolled in the
study, gave written informed consent to the study par-
ticipation according to the institutional guidelines of the
local Ethic Committee (Fatebenefratelli hospital “San
Giovanni di Dio” - Brescia, Italy), were of Caucasian
heritage for at least two generations, lived in northern
Italy, were unrelated to other prospective participants,
and fulfilled predefined group-specific inclusion and ex-
clusion criteria. A concise but unequivocal explanation
about the aims of the study was included on the written
consent form. The participants also received an explicit
guarantee of anonymity. A unique number linked all the
individual data.
The patients were enrolled from those voluntarily ad-
mitted to the Brescia University and Spedali Civili
Psychiatric Unit or the Brescia IRCCS Fatebenefratelli.
The inclusion criteria were a DSM-IV-TR diagnosis of
schizophrenia and a level of understanding and attention
judged sufficient to give true informed consent; a
lifetime comorbidity with other DSM-IV-TR Axis I dis-
orders was an exclusion criterion. All participants under-
went detailed clinical interviews, implemented, when
required, by DSM-IV-TR adjusted versions of the Struc-
tural Clinical Interview for DSM-IV Axis I Disorders,
Clinician Version (SCID-CV) [14]. Patients were also
evaluated about schizophrenia subtype and age at the
onset of the disorder. To attribute the schizophrenia
subtype, a checklist of the symptoms dominating the
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4 weeks was used.
For the age at onset of schizophrenia, the appearance
of the first psychotic symptoms represented the pre-
identified operational cut-off; in order to reach as accur-
ate estimates as possible, direct information from the
patients was systematically retrieved along with data
obtained from at least one close relative plus, when
existing, previous medical records.
The controls were randomly recruited through different
sources (hospital visitors, cultural and elderly associations,
trade unions, word of mouth and newspaper advertising).
They were screened for DSM-IV Axis I disorders by
expert psychologists using the Mini-International Neuro-
psychiatric Interview (M.I.N.I.) [15]. Only healthy volun-
teers without a history of drug or alcohol abuse or
dependence and without a personal or first-degree family
history of psychiatric disorders were enrolled in the study.
Subjects who obtained a score lower than 27/30 in the
Mini Mental State Examination (M.M.S.E.) [16] were ex-
cluded as well.
When compared with controls, patients presented a
younger age at the time of the genotyping (42.4 ± 12.5
vs. 45.4 ± 16.7 years, p < 0.01) and a higher proportion of
males (67.8% vs. 43.9%, p < 0.001). The majority of the
schizophrenia patients (60.1%) were affected by the para-
noid subtype. Furthermore, among the 290 patients who
provide sufficiently informative data, the age at the onset
of schizophrenia was 23.8 ± 6.4 years, with an anticipa-
tory effect for males with respect to females (23.2 ± 6.1
vs. 25.2 ± 6.8 years, p < 0.001).
Because controls and patients were not matched for
sex or age, these variables were retained in the logistic/
multinomial regression model analyses to control for po-
tential confounding effects. The log-transformed age and
age at onset were calculated to improving their approxi-
mation to a Gaussian distribution.
Genotyping
The Puregene DNA purification kit (Gentra System) was
used to extract DNA from each sample.
A panel of 47 SNPs were selected as tagging SNPs (by
SNPbrowser version 3.5, [17]) from the HapMap Project
(phase II, data release #21a, CEPH data set) to evenly
encompass the regions of the DAO, DAOA, PPP3CC,
and DTNBP1 genes, including the 5’ and 3’ boundaries.
The 47 SNPs panel was genotyped for the whole patient-
control cohort using the SNPlex procedure in accord-
ance with the current manufacturer’s protocol (Applied
Biosystems, Foster City, CA, USA).
To minimise type I errors due to incorrect genotype
assignment and excess of multiple tests, the inclusion of
the SNPs in the association analyses was restricted to
those with 1) no significant deviation from Hardy-Weinberg equilibrium (HWE) in both patients and con-
trols (exact test p < 0.001); 2) a Minor Allele Frequency
(MAF) greater than 0.1; 3) a completion rate for geno-
typing greater than 90%. 32 SNPs fulfilled these criteria
after genotyping. A more in-depth description and a
quality control were reported in Additional file 1.
Consequently, the analyses were conducted on sam-
ples of 862, 877, 861, and 855 individuals for DAO
(N = 386 patients and N = 476 controls), DAOA (N = 391
patients and N = 486 controls), PPP3CC (N = 384 pa-
tients and N = 477 controls), and DTNBP1 (N = 382 pa-
tients and N = 473 controls), respectively.
Statistical analyses
PLINK software version 1.07 (http://pngu.mgh.harvard.
edu/~purcell/plink) was used for HWE patient-control
comparisons of all polymorphisms and phased haplotypes.
For the PLINK software, a nominal level of signifi-
cance of p = 0.05 was accepted and corrected according
to the 10000 permutation procedure for genotype fre-
quencies and Bonferroni’s correction for allele frequen-
cies for all genotype/allele association tests. In details
these analyses were conducted separately for each gene
considering 6 SNPs for DAO, 6 SNPs for DAOA, 8 SNPs
for PPP3CC and 12 for DTNBP1.
Haploview program version 4.2 [18] was used to evalu-
ate differences in allele frequencies, calculate the pair-
wise Linkage Disequilibrium (LD) between SNPs, and
estimate haplotype frequencies for each block of linkage.
Patient-control differences in haplotype distribution
were determined by 10000 permutation test.
Case-control sliding window haplotypes, χ2 tests and
10000 permutation tests were performed utilising the
Haploview program version 4.2. These window sizes were
chosen to approximately examine haplotypes within the
specific LD blocks identified by LD analyses. Moreover, the
sliding window approach was chosen to systematically ex-
plore other haplotypes in areas of lower LD [18]. The cor-
rections were performed considering each gene separately.
Only the allele frequencies of the haplotypes >5% were
included in the analyses, those <5% the haplotypes were
excluded.
Phased haplotypes aimed at assigning the two most
plausible haplotypes to each sample were performed by
PLINK. When logistic regression analyses demonstrated
patient-control differences in the allele frequencies of a
specific haplotype, the phased haplotype was clustered
to obtain the relative genotypes and carriers. The odd
ratios (ORs) with corresponding 95% confident intervals
(CIs) were used to quantify the associations between the
clustered genotypes/carriers of the haplotypes and
schizophrenia.
Based on the sample size, the QUANTO program
showed that the study had an 80% power to detect an
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0.4 in the sample of cases-controls and OR ≥ 1.8 in the
males and females sample, and assuming a priori a 1%
risk for schizophrenia in the general population.
All the primary analyses were also supplemented by a
series of secondary analyses that included gender, diag-
nostic subtypes, and age at onset. These secondary
analyses were as follows: 1) Forward logistic regression
analyses, with group (patients vs. controls) as the
dependent variable and allele/haplotype (carriers vs.
others), gender, and allele/haplotype by gender inter-
action as independent variables, were utilised to estab-
lish the presence of a putatively different effect of the
allele/haplotype between the two sexes. Log-transformed
age was also entered as covariate. The effects were
expressed as ORs with their corresponding 95% CIs. 2).
Multinomial logistic regression analyses, with illness sta-
tus (control = -1, non-paranoid schizophrenia = 0, para-
noid schizophrenia = 1) as the dependent variable and
allele/haplotype presence, gender, and allele/haplotype
by gender interaction as predictive variables and log-
transformed age as covariate, were utilised to define the
possible specific effects of the allele/haplotype in definite
schizophrenia subtypes. The analyses were performed
considering the controls as the reference category. 3)
Factorial analyses of variance (ANOVA) of the log-
transformed age of schizophrenia onset, also including
the gender, were utilised to assess the allele/haplotype
influence on the log-transformed onset of disorder and
eventual interactions with the gender.
Goodness of fit was assessed by means of the Hosmer
and Lemeshow test.
The gene-gene interactions between the most signifi-
cant SNPs were assessed by logistic regression methods.
All of these analyses were performed using SPSS soft-
ware, version 12.0 (SPSS Inc. Chicago, IL).
Results
32 tagSNPs were analyzed in the statistical analyses.
DAO
The six selected polymorphisms did not evidence patient-
control differences in genotype, allele, or carrier frequen-
cies (for details, see Additional file 1: Table S1). The same
was true for the haplotype analysis.
There were 9 sliding windows for DAO gene. According
to the LD panel (see Additional file 1: Table S2), we
conducted the analyses considering the rs3741775 along
with the other single SNPs, rs3918347 along with the
other single SNPs and between them, setting a p value sig-
nificant of 0.006 (0.05/9).
Secondary analyses of the haplotypes instead revealed
effects related to gender and the diagnostic subtype of
schizophrenia. In particular, haploview analyses showeda patient-control difference in the allele estimated GT
diplotype (rs2070586 A/G-rs3741775 G/T) limited to
females (p = 0.003, pcorrect = 0.009; Table 1): after phased
analysis and clusterisation, the genotype frequencies
of the estimated/phased GT diplotype were different
(p = 0.002), with the carriers more represented in female
controls (p = 0.017, OR = 0.58, 95% CI: 0.37-0.90). No as-
sociation was found in males (p = 0.92, OR = 0.98, 95%
CI: 0.65-1.47). The male-female difference had been
confirmed by the interaction between gender and the
estimated/phased GT diplotype carrier (p = 0.003, OR =
0.43, 95% CI: 0.24-0.75).
Multinomial logistic regression analysis demonstrated
the presence of an association between estimated/phased
GT diplotype female carriers when paranoid schizophre-
nia patients were compared to healthy controls (p = 0.01,
relative risk ratio = 0.52, 95% CI: 0.31-0.87, controls as
reference category, Additional file 1: Table S3B). No sig-
nificant results were observed when the non-paranoid
patients were compared to the controls.
No significant effects emerged regardless of the geno-
type, or carrier stratified for diagnostic subtype and age
at schizophrenia onset (consistently, p > .10).
DAOA
The primary analyses of the 6 DAOA gene polymor-
phisms failed to detect any association (for details, see
Additional file 1: Table S1); this was true also when the
haplotype distributions were considered. All the second-
ary analyses were equally negative.
PPP3CC
The eight polymorphisms chosen for the PPP3CC gene
were unrelated to schizophrenia risk in genotype, allele,
and carrier after multiple correction (for details see
Additional file 1: Table S1).
There were 11 sliding windows for PPP3CC. According
to LD panel (see Additional file 1: Table S2), we conducted
the analyses considering rs4872499 along with two SNPs
in the Block 1 and along with all SNPs of the Block 2, set-
ting the p value to 0.005 (0.05/11).
In relation to the haploview analysis, a patient-control
difference emerged in the allele frequency for the esti-
mated CAG triplotype in the SNP window rs4872499
T/C-rs11780915 A/G-rs13271367 G/A (p = 7×10-4,
pcorrect = 0.001, Table 1). Similarly, the clustered geno-
type frequencies of the estimated/phased CAG triplotype
differed between cases and controls (p = 0.004), with the
carriers showing a higher frequency in the control popu-
lation (p = 0.002, OR = 0.59, 95% CI: 0.43-0.82).
Secondary analyses supported a significant effect of
single SNPs rs11780915 and rs13271367 in males group,
with carrier A rs11780915 and carrier G rs13271367
more represented in patients group (pcorrect = 0.02, OR =
Table 1 Estimated haplotype distributions for selected D-amino acid oxidase (DAO), protein phosphatise 3 catalytic
subunit gamma isoform (PPP3CCC) and dystrobrevin-binding protein 1 (DTNBP1) single nucleotide polymorphisms in
patients with schizophrenia and control subjects and in females and males samples
DAO Haplotype (rs2070586|rs3741775)
Haplotype Patientsa Controlsb χ2 DF P P correctc
Total samples N = 386 N = 476
GG 0.42 0.40 0.69 1 0.41
AT 0.21 0.19 1.40 1 0.24
GT 0.37 0.41 3.70 1 0.05 0.13
Females N = 126 N = 270
GG 0.43 0.39 1.31 1 0.25
AT 0.23 0.17 3.88 1 0.05 0.11
GT 0.33 0.44 8.65 1 0.003 0.009
Males N = 260 N = 206
GG 0.41 0.41 0.01 1 0.92
AT 0.20 0.21 0.10 1 0.75
GT 0.39 0.38 0.03 1 0.86
PPP3CC Haplotype (rs4872499|rs11780915|rs13271367)
Haplotype Patientsa Controlsb χ2 DF P P correctc
Total samples N = 383 N = 476
CGA 0.61 0.56 3.50 1 0.06
TAG 0.22 0.21 0.62 1 0.43
CAG 0.13 0.19 11.56 1 7x10-4 0.001
others 0.03 0.03
Females N = 125 N = 269
CGA 0.60 0.57 0.63 1 0.43
TAG 0.22 0.17 2.65 1 0.10
CAG 0.12 0.20 7.60 1 0.006 0.04
others 0.05 0.05
Males N = 258 N = 207
CGA 0.61 0.55 3.52 1 0.06
TAG 0.22 0.25 1.14 1 0.29
CAG 0.13 0.17 2.98 1 0.08
others 0.03 0.02
DTNBP1 Haplotype (rs6459409|rs9476886)
Total samples N = 381 N = 473
CT 0.17 0.20 2.18 1 0.14
TT 0.13 0.12 0.78 1 0.38
TC 0.69 0.68 0.28 1 0.60
Females N = 125 N = 270
CT 0.20 0.17 0.62 1 0.43
TT 0.15 0.12 1.23 1 0.27
TC 0.65 0.70 1.84 1 0.17
Sacchetti et al. BMC Medical Genetics 2013, 14:33 Page 5 of 9
http://www.biomedcentral.com/1471-2350/14/33
Table 1 Estimated haplotype distributions for selected D-amino acid oxidase (DAO), protein phosphatise 3 catalytic
subunit gamma isoform (PPP3CCC) and dystrobrevin-binding protein 1 (DTNBP1) single nucleotide polymorphisms in
patients with schizophrenia and control subjects and in females and males samples (Continued)
Males N = 256 N = 203
CT 0.16 0.24 8.55 1 0.003 0.006
TT 0.12 0.11 0.34 1 0.56
TC 0.71 0.65 3.77 1 0.05 0.14
ahaplotype frequencies in schizophrenia patients.
bhaplotype frequencies in control subjects.
DF = degree of freedom.
cPcorrect after 10000 permutations.
Sacchetti et al. BMC Medical Genetics 2013, 14:33 Page 6 of 9
http://www.biomedcentral.com/1471-2350/14/331.79, 95% CI: 1.19-2.67 and pcorrect = 0.04, OR = 1.70,
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Concerning the haplotype analysis, there was a signifi-
cant effect of the estimated CAG triplotype in the female
group, with p correct value of 0.04 for the allele frequen-
cies (Table 1). According to the correction for sliding
window approach, this difference was lost (p = 0.006).
However significant results were also observed for the
clustered genotype (p = 0.03). As for the carriers, over-
representation was found in female controls (p = 0.01,
OR = 0.53, 95% CI: 0.32-0.87) but not in males (p = 0.09,
OR = 0.68, 95% CI: 0.43-1.06). This female-specific pro-
tective effect was corroborated to some degree by the
interaction between the estimated/phased CAG triplotype
carriers and gender (p = 0.02; OR = 0.52; 95% CI: 0.29-0.91).
Multinomial logistic regression analysis demonstrated
the presence of an association between estimated/phased
CAG triplotype female/total sample carriers when para-
noid schizophrenia patients were compared to healthy
controls (p = 0.04, relative risk ratio = 0.54, 95% CI: 0.30-
0.96, controls as reference category, Additional file 1:
Table S3B). No significant results were observed when
the non-paranoid patients were compared to the controls.
The ANOVA analysis showed that age at the onset of
schizophrenia was not accounted for by this haplotype
(consistently, p > .10) or any of the single polymorphisms.DTNBP1
The single marker analysis of 12 tagSNPs in the total
sample (for details, see Additional file 1: Table S1) failed
to demonstrate patient-control differences in allele and
genotype frequencies, both in the recessive and the
dominant inheritance model. The haplotype analyses
also did not support any association with schizophrenia.
When the SNP frequencies were analysed in relation
to gender, protective effect in males was observed for
rs6459409 (pcorrect = 0.02, carrier C, OR = 0.55, 95% CI:
0.37-0.81).
Considering rs6459409 along with all other SNPs (see
Additional file 1: Table S2), we calculated 11 sliding win-
dows, setting a p value to 0.005 (0.05/11). The haploview
analyses in males showed CC (rs10456773 C/T -rs6459409 C/T) and CT (rs6459409 C/T -rs9476886 T/
C) allele haplotypes having some protective association
with schizophrenia (pcorrect = 0.03, pcorrect = 0.006 respect-
ively) (Table 1), whereas CT (rs10456773-rs6459409)
haplotype showed a risk association (pcorrect = 0.01).
Because the estimated/phased CT diplotype (rs6459409-
rs9476886) was more significant compared to the others,
the male carriers were also evaluated, and a protective
effect on schizophrenia (p = 3×10-4, OR= 0.46, 95% CI:
0.30-0.70) emerged. No association was found in females
(p = 0.44, OR= 1.20, 95% CI: 0.76-1.88). The presence of a
significant interaction with gender (p = 5×10-6, OR= 3.69,
95% CI: 2.10-6.49) further supported these two findings.
The stratification of the polymorphisms (genotypes
and carriers) and estimated/phased haplotypes (CT car-
riers vs. others) according to age of onset and diagnostic
subtypes failed to detect significant associations (consist-
ently, p > .10).
Interaction effects
Due to the significant results for the estimated/phased
DAO GT diplotype and PPP3CC CAG triplotype carriers
in females, we verified whether the effects obtained were
stronger through an interaction analysis. The results
showed that the females carrying both the CAG and GT
haplotypes had a 66% (p = 0.003, OR = 0.34, 95% CI:
0.17-0.70, Additional file 1: Table S3A) lower risk of de-
veloping schizophrenia relative to non-CAG or -GT
carriers. All of the other interactions showed negative
results.
Discussion
The primary analyses did not demonstrate associations
between schizophrenia and any of the 32 studied DAOA,
DAO, PPP3CC, and DTNBP1 SNPs. This finding is in
line with other studies performed in larger samples
[19-23].
The secondary analyses instead confirmed effects of
the DAO, PPP3CC, and DTNBP1 genes on schizophre-
nia susceptibility; these effects were mediated not only
by the gender and paranoid/non-paranoid dichotomy
but also by epistatic/interaction mechanisms.
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ary analyses may be reconciled assuming that the DAO,
PPP3CC, and DTNBP1 genes modulate the susceptibility
for schizophrenia only under definite circumstances.
Gender-related differences in schizophrenia are far
from a novel finding: an extensive literature indicates
that males and females differ from each other in some
psychopathological domains, treatment efficacy, and the
presence of structural and brain abnormalities [24-26].
The influence of gender on schizophrenia has been re-
lated to oestrogens [25,26], neurodevelopment [27,28],
and lateralization [29].
However, it is possible that in schizophrenia, as in
many other complex disorders [30], several genes or
genetic variations may affect susceptibility to the dis-
order in relation to the gender of the patient both for fe-
male or male specific protective or risk effects [13,31-33].
Present data concerning an influence of gender not
only on the DAO, DTNBP1, and PPP3CC genes but also
on the epistatic effect between the DAO and PPP3CC
genes undoubtedly fit well within this scenario and have
some specific antecedents.
In particular, in a Korean population, the DAO gene
evidenced gender-specific differences in relation to the
allele distributions and haplotypes of three SNPs,
rs2070586, rs2070587, and rs3918347, which acted as
risk or protective factors in relation to the sex of the pa-
tients [34]. The Korean study [34] and the current study
differ in the haplotype combination involved; this dis-
crepancy could be explained, as already reported [23], by
ethnic background differences in the DAO gene, with
variations between Asians and Caucasians in both allele
frequencies and linkage patterns (http://hapmap.ncbi.
nlm.nih.gov/index.html.en). Furthermore, animal studies
have suggested that the DAO activity differs according
to sex, most likely due to the effects of sex hormones
[35,36]. Given the effect of oestradiol in reducing DAO
activity in the liver tissues of female guinea pigs [35],
oestrogens could have a protective effect on schizophre-
nia by preventing increases of DAO activity and subse-
quent NMDA hypofunction. In particular, the presence
of a hormonally influenced transcriptional regulation of
NMDA genes, mainly the DAO gene, could explain our
results in females.
Since the significant interaction of gender and DAO
and PPP3CC genes, an epistatic effect was performed
and a 66% lower risk of developing schizophrenia was
observed among females with the PPP3CC CAG
triplotype and the DAO GT diplotype carriers as com-
pared with non-CAG or -GT haplotype carriers of the
same sex, whereas the CAG triplotype and the GT
diplotype alone showed a 47% and a 42% lower risk for
schizophrenia, respectively. Therefore, it could be
hypothesised not only that the major protective effect ofDAO could be mediated by the non-interaction with
oestradiol [35,36], but also that the potentiation played
by PPP3CC may be sustained by some interaction with
the sex hormone pathway.
Other relevant findings come from the analysis of
DTNBP1 gene polymorphisms and haplotypes: the ob-
servation of an influence of DTNBP1 on schizophrenia
susceptibility in males could indicate the presence of sex-
specific effect and/or of interactions with sex hormones.
With respect to the diagnostic subtype, the 42% and
47% excess of the estimated/phased DAO GT diplotype
and PPP3CC CAG triplotype female carriers respectively
found in controls compared to patients did not increase
when exclusively female paranoid patients were consid-
ered (48% and 46% respectively). Therefore, the protect-
ive effect of the both DAO GT diplotype and PPP3CC
CAG triplotype carriers is reasonably not paranoid-
specific but comparable to schizophrenia as a whole.
Similar results were obtained for PPP3CC CAG triplotype
carriers and paranoid patients versus schizophrenia as
whole (see Additional file 1: Table S3B). Although this pu-
tative involvement of DAO and PPP3CC in this specific
subgroup was observed also for other genes related to the
same glutamatergic/NMDAR regulation [37-40] associ-
ated with paranoid schizophrenia, a larger sample is
needed to confirm this finding.
The present study requires some further comments.
Although our SNPs are substantially informative due to
their distribution covering the whole genes, they do not
all correspond to those used in other studies. Thus, in
the case of the analysis of the same SNP, our association
can be attributed to stratification, even though we can-
not exclude other confounding clinical phenotypes that
manifest differently in male and female schizophrenia
patients, such as treatment response, comorbid mood
symptoms, and cognitive impairment, rather than a
direct link between these genes and female/male schizo-
phrenia. In the case of positive associations with differ-
ent SNPs in the same gene, we cannot exclude the
replica value because haplotype-specific functional varia-
tions have not been analysed. A recent GWAS study on
bipolar patients showed that there is likely common gen-
etic variation associated with the disorder near exons
(±10 kb) that could be identified in larger studies and
also provided a framework for assessing the potential
for replication when combining results from multiple
studies [41].
Moreover the major limitation of this paper is the rela-
tively small sample size mainly after stratification for
gender and diagnostic subtypes; however, because of we
have based our study on the phenotype dissection strat-
egy, we have computed the power for higher OR. This
represents a suggestion for future replications in larger
samples.
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http://www.biomedcentral.com/1471-2350/14/33Finally, there is a formal possibility of type I error due
to the limited number of samples available for analyses
after different stratifications. However mainly in the case
of stratifications by sex, significant results persist even
after correction for multiple testing in the subgroups,
and this makes it reasonable to assume that there could
be only a low possibility of type I error in the results.
Conclusions
This study represents the first evidence of association of 3
NMDA-receptor-mediated signalling genes, DAO, DAOA,
PPP3CC, and DTNBP1 in an Italian population. In par-
ticular DAO, PPP3CC, and DTNBP1, might be differen-
tially involved in schizophrenia susceptibility according to
gender and gene interaction mechanisms. Although the
results are preliminary and needed replication in a larger
sample, the present results underline the need for more
systematic use of the phenotype “dissection” strategy and
the search for interaction effects to strengthen the inform-
ative power of genetic association studies.
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